Free Trial
NASDAQ:MRSN

Mersana Therapeutics (MRSN) Stock Price, News & Analysis

Mersana Therapeutics logo
$0.62 +0.00 (+0.68%)
As of 01/17/2025 04:00 PM Eastern

About Mersana Therapeutics Stock (NASDAQ:MRSN)

Key Stats

Today's Range
$0.58
$0.63
50-Day Range
$0.61
$2.68
52-Week Range
$0.56
$6.28
Volume
7.70 million shs
Average Volume
1.55 million shs
Market Capitalization
$76.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.57
Consensus Rating
Moderate Buy

Company Overview

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Mersana Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
84th Percentile Overall Score

MRSN MarketRank™: 

Mersana Therapeutics scored higher than 84% of companies evaluated by MarketBeat, and ranked 179th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Mersana Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Mersana Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Mersana Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Mersana Therapeutics are expected to grow in the coming year, from ($0.61) to ($0.59) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Mersana Therapeutics is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Mersana Therapeutics is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Mersana Therapeutics has a P/B Ratio of 2.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Mersana Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    7.16% of the outstanding shares of Mersana Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Mersana Therapeutics has a short interest ratio ("days to cover") of 4.2.
  • Change versus previous month

    Short interest in Mersana Therapeutics has recently decreased by 0.67%, indicating that investor sentiment is improving.
  • Dividend Yield

    Mersana Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Mersana Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.16% of the outstanding shares of Mersana Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Mersana Therapeutics has a short interest ratio ("days to cover") of 4.2.
  • Change versus previous month

    Short interest in Mersana Therapeutics has recently decreased by 0.67%, indicating that investor sentiment is improving.
  • News Sentiment

    Mersana Therapeutics has a news sentiment score of -0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 13 news articles for Mersana Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    15 people have searched for MRSN on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Mersana Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Mersana Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $28,512.00 in company stock.

  • Percentage Held by Insiders

    11.80% of the stock of Mersana Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    93.92% of the stock of Mersana Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Mersana Therapeutics' insider trading history.
Receive MRSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mersana Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRSN Stock News Headlines

Mersana Therapeutics CEO sells $2,618 in stock
Grab This Altcoin Before Trump's Crypto Announcement
Grab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which is why I'm recommending ONE coin to all investors right now.
See More Headlines

MRSN Stock Analysis - Frequently Asked Questions

Mersana Therapeutics' stock was trading at $1.43 at the beginning of the year. Since then, MRSN stock has decreased by 56.7% and is now trading at $0.6186.
View the best growth stocks for 2025 here
.

Mersana Therapeutics, Inc. (NASDAQ:MRSN) announced its quarterly earnings results on Wednesday, November, 13th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.08. Mersana Therapeutics's revenue for the quarter was up 63.6% on a year-over-year basis.

Mersana Therapeutics (MRSN) raised $75 million in an IPO on Wednesday, June 28th 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Mersana Therapeutics' top institutional investors include SG Americas Securities LLC (0.09%) and Avanza Fonder AB (0.05%). Insiders that own company stock include Andrew A F Hack, Timothy B Lowinger, Anna Protopapas, Martin H Jr Huber, Brian Deschuytner, Alejandra Carvajal, Ashish Mandelia, Mohan Bala, Arvin Yang and Tushar Misra.
View institutional ownership trends
.

Shares of MRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Mersana Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Saia (SAIA), Rambus (RMBS), Advanced Micro Devices (AMD) and Arista Networks (ANET).

Company Calendar

Last Earnings
11/13/2024
Today
1/20/2025
Next Earnings (Estimated)
2/26/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MRSN
Fax
N/A
Employees
150
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.57
High Stock Price Target
$9.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+800.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-171,670,000.00
Net Margins
-214.20%
Pretax Margin
-212.99%

Debt

Sales & Book Value

Annual Sales
$36.85 million
Book Value
$0.31 per share

Miscellaneous

Free Float
108,956,000
Market Cap
$76.42 million
Optionable
Optionable
Beta
1.43
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

This page (NASDAQ:MRSN) was last updated on 1/20/2025 by MarketBeat.com Staff
From Our Partners